Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-27.13%
|
$571,500
$381.37 P/Share
|
|
Nov 17
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|
|
Nov 09
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
2,334
-37.82%
|
$858,912
$368.03 P/Share
|
|
Nov 08
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
7,666
-19.15%
|
$2,690,766
$351.79 P/Share
|
|
Nov 08
2021
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
9,000
-26.41%
|
$3,150,000
$350.8 P/Share
|
|
Oct 31
2021
|
Lai Wang Global Head of R&D |
BUY
Bona fide gift
|
Indirect |
58,188
+50.0%
|
-
|
|
Oct 31
2021
|
Lai Wang Global Head of R&D |
SELL
Bona fide gift
|
Indirect |
58,188
-100.0%
|
-
|
|
Oct 19
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-41.36%
|
$558,000
$372.39 P/Share
|
|
Oct 19
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|
|
Sep 28
2021
|
Lai Wang Global Head of R&D |
SELL
Bona fide gift
|
Direct |
58,188
-25.0%
|
-
|
|
Sep 20
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
6,000
-30.64%
|
$2,394,000
$399.96 P/Share
|
|
Sep 20
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$714,000
$119.96 P/Share
|
|
Sep 15
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,158
-51.27%
|
$9,887,724
$378.57 P/Share
|
|
Sep 15
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
190,203
-9.87%
|
$5,515,887
$29.31 P/Share
|
|
Sep 14
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
37,877
-41.69%
|
$13,862,982
$366.33 P/Share
|
|
Sep 14
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
157,600
-6.5%
|
$4,412,800
$28.22 P/Share
|
|
Sep 13
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
12,901
-46.67%
|
$4,631,459
$359.46 P/Share
|
|
Sep 10
2021
|
Amgen Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
165,529
+0.87%
|
$49,989,758
$302.06 P/Share
|
|
Sep 02
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
545
-100.0%
|
$178,215
$327.18 P/Share
|
|
Sep 02
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,499
-35.78%
|
$8,035,672
$328.65 P/Share
|
|
Sep 01
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
545
+50.0%
|
-
|
|
Sep 01
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
542
-100.0%
|
$168,020
$310.53 P/Share
|
|
Sep 01
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
7,124
+2.23%
|
-
|
|
Sep 01
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,501
-51.85%
|
$8,287,825
$325.99 P/Share
|
|
Sep 01
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
127,558
-1.73%
|
$3,061,392
$24.53 P/Share
|
|
Aug 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
542
+50.0%
|
-
|
|
Aug 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
7,163
+2.29%
|
-
|
|
Aug 31
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,281
-28.61%
|
$10,387,143
$303.69 P/Share
|
|
Aug 31
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
76,800
-2.04%
|
$1,766,400
$23.67 P/Share
|
|
Aug 05
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,362
-23.63%
|
$3,502,356
$338.07 P/Share
|
|
Aug 05
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,100
-0.8%
|
$852,500
$25.82 P/Share
|
|
Aug 04
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,747
-47.77%
|
$10,920,968
$344.77 P/Share
|
|
Aug 04
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
49,100
-1.11%
|
$1,276,600
$26.08 P/Share
|
|
Aug 03
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,959
-13.83%
|
$14,014,306
$334.29 P/Share
|
|
Aug 03
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,400
-0.85%
|
$1,035,000
$25.17 P/Share
|
|
Jul 22
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,316
-23.24%
|
$3,564,540
$315.58 P/Share
|
|
Jul 22
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,900
-1.05%
|
$1,331,700
$23.71 P/Share
|
|
Jul 21
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,260
-40.83%
|
$4,715,340
$309.11 P/Share
|
|
Jul 21
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,900
-0.21%
|
$285,600
$24.58 P/Share
|
|
Jul 20
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,995
-47.61%
|
$5,102,405
$319.54 P/Share
|
|
Jul 20
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,700
-0.47%
|
$664,800
$24.61 P/Share
|
|
Jul 15
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
21,000
-62.84%
|
$6,993,000
$333.21 P/Share
|
|
Jul 15
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+35.32%
|
$3,171,000
$151.6 P/Share
|
|
Jul 08
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,881
-30.67%
|
$5,050,158
$318.31 P/Share
|
|
Jul 08
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
51,300
-0.84%
|
$1,231,200
$24.24 P/Share
|
|
Jul 07
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,046
-29.71%
|
$8,256,582
$317.49 P/Share
|
|
Jul 07
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,700
-0.64%
|
$1,017,500
$25.14 P/Share
|
|
Jul 06
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
10,180
-48.22%
|
$3,318,680
$326.45 P/Share
|
|
Jul 06
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,075
-46.1%
|
$4,262,450
$326.28 P/Share
|
|
Jul 06
2021
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
44,300
-0.65%
|
$1,107,500
$25.42 P/Share
|